Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2023-02-10 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
112年1月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (美時) providing information on fund loans and endorsement guarantees for the current and previous month, including limits and balances. It contains no detailed financial statements or comprehensive analysis, and the length is only 629 characters, indicating it is a short regulatory disclosure rather than a full report. There is no indication of an annual or interim report, audit report, or earnings release. The content fits the profile of a general regulatory announcement or compliance disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-02-10 Chinese
112年1月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a revenue summary report for a specific month (January 2023) showing net operating revenue figures and percentage changes compared to the previous year. It includes explanations for revenue changes and accounting standards references. The document is short (803 characters) and provides financial data for a short period (monthly). It is not a full annual or quarterly report but a brief financial summary. This fits the definition of a Fund Information / Factsheet (FS), which is a brief summary of key company financials and market info. There is no indication it is an announcement or a regulatory filing, nor is it a detailed report or presentation.
2023-02-10 Chinese
112年01月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, and other executives. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or meeting materials. There is no indication of it being a full financial report, earnings release, or regulatory certification. The document is a report of personal share transactions by company directors and executives, which matches the definition of Director's Dealing (DIRS). The document length is substantial and contains detailed data, not just an announcement or summary.
2023-02-10 Chinese
112年01月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders and related parties of the company 美時化學製藥股份有限公司. It lists positions such as chairman, directors, independent directors, general manager, and other executives along with their shareholdings and pledged shares. The document does not contain financial statements, earnings data, or management discussion. It is a disclosure of insider shareholdings and pledges, which corresponds to reporting of personal share transactions or holdings by company directors and executives. There is no indication of it being an announcement of voting results, capital changes, or other categories. The document length is 4350 characters, which is relatively short but contains detailed insider shareholding data. Therefore, the best fitting category is Director's Dealing (DIRS).
2023-02-10 Chinese
澄清中央社112/02/06報導
Regulatory Filings Classification · 95% confidence The document is a short announcement (802 characters) from a company clarifying a news report about a licensing agreement. It includes details about the agreement and payment terms but does not contain any financial statements, detailed financial analysis, or comprehensive report content. It is a regulatory announcement clarifying a specific event rather than a full report or financial filing. The document is not a report itself but a disclosure or clarification statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-02-06 Chinese
公告本公司Nintedanib Capsules學名藥獲得美國FDA暫定 審查核可
Regulatory Filings Classification · 95% confidence The document is a short announcement (869 characters) from a listed company (美時) about receiving tentative FDA approval for a generic drug (Nintedanib Capsules). It includes details about the event date, company name, and impact on shareholders. There are no financial statements, no detailed financial data, no management discussion, or report attachments. The document is a regulatory announcement about a material event affecting the company, fitting the description of a Regulatory Filing (RNS). It is not a full report, earnings release, or presentation, and it is not a report publication announcement since it contains substantive event information rather than just a notice of report availability.
2023-01-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.